Cefditoren sodium is a third generation cephalosporin antibiotic.
TOKU-E offers three forms of cefditoren: cefditoren (C100), cefditoren sodium (C094), and cefditoren pivoxil (C050). Cefditoren sodium is soluble in aqueous solution, and cefditoren pivoxil is soluble in fat.
| Mechanism of Action | Like β-lactams, cephalosporins interfere with PBP (penicillin binding protein) activity involved in the final phase of peptidoglycan synthesis. PBP’s are enzymes which catalyze a pentaglycine crosslink between alanine and lysine residues providing additional strength to the cell wall. Without a pentaglycine crosslink, the integrity of the cell wall is severely compromised and ultimately leads to cell lysis and death. Resistance to cephalosporins is commonly due to cells containing plasmid encoded β-lactamases. |
| Spectrum | Cefditoren is a broad spectrum antibiotic commonly used against bacteria responsible for community acquired pneumonia and pharyngitis. |
| Microbiology Applications | Cefditoren sodium can be used to study antibiotic effects against group A Streptococcus and other microbes responsible for phayrngitis. |
| Molecular Formula | C19H17N6NaO5S3 |
| References | Poveda, J. L., et al. "Cefditoren Pivoxil: A New Oral Cephalosporin for Skin, Soft Tissue and Respiratory Tract Infections." Medline 19.3 (n.d.): 231-46.www.ncbi.gov. Web. 27 Aug. 2012. Georgopapadakou, N. H. "Mechanisms of Action of Cephalosporin 3'-quinolone Esters, Carbamates, and Tertiary Amines in Escherichia Coli." American Society for Microbiology 37.3 (1992): 559-65. Antimicrobial Agents and Chemotherapy. Web. 21 Aug. 2012. |
| MIC | Bordetella pertussis | 0.25|| Burkholderia cepacia| 16 － >128|| Citrobacter freundii| 0.125 － >128|| Citrobacter spp.| 1 － >16|| Comamonas spp.| 16|| Enterobacter aerogenes| 0.5 － >16|| Enterobacter cloacae| 0.125 － 128|| Enterococcus faecalis| 0.5 － >128|| Enterococcus faecium| 16 － >128|| Escherichia coli| 0.063 － 2|| Escherichia coli (ESBL)| 4 － 32|| Escherichia coli (quinolone-resistant)| 0.03 － 2|| Haemophilus influenzae| ≥0.063 － 0.25|| Haemophilus influenzae (ESBL)| ≤0.008 － 0.5|| Klebsiella pneumonia| ≥0.063 － 64|| Legionella pneumophila| 0.25 － 16|| Moraxella catarrhalis| <0.008 － 2|| Moraxella catarrhalis (ESBL)| ≤0.008 － 0.12|| Morganella morganii| 0.063 － 8|| Pantoea agglomerans| 1|| Proteae (indole-positive)| >0.12 － >16|| Proteus mirabilis| 0.03 － 0.25|| Proteus vulgaris| 0.032 － 128|| Providencia rettgeri| 0.016 － 64|| Pseudomonas aeruginosa| 32 － >128|| Salmonella spp.| 0.25 － 0.5|| Serratia marcescens| 0.5 － >128|| Staphylococci (coagulase-negative)| >2 － >16|| Staphylococcus aureus (methicillin-resistant)| 1 － >128|| Staphylococcus aureus (methicillin-susceptible)| 0.25 － 8|| Staphylococcus epidermidis| 1 － 16|| Staphylococcus epidermidis (methicillin-resistant)| 2 － >128|| Staphylococcus epidermidis (methicillin-susceptible)| 0.063 － 4|| Stenotrophomonas maltophilia| 32 － >128|| Streptococci (Viridans group)| ≤0.008 － 8|| Streptococci (β-hemolytic)| ≤0.008 － 0.06|| Streptococcus agalactiae| 0.032 － 0.063|| Streptococcus pneumonia| ≤0.008 － 1|| Streptococcus pneumonia (methicillin-resistant)| 0.25 － 4|| Streptococcus pneumonia (methicillin-susceptible)| 0.008 － 0.5|| Streptococcus pneumonia (pbp2x and pbp2b or pbp1a and pbp2x genes abnormal + penicillin)| 0.063 － 1|| Streptococcus pneumonia (pbp2x gene abnormal + penicillin-intermidiate)| 0.016 － 0.25|| Streptococcus pneumonia (pbpla, pbp2x, and pbp2b genes abnormal + penicillin-resistant)| 0.25 － 8|| Streptococcus pneumonia (penicillin-intermediate)| 0.015 － 2|| Streptococcus pneumonia (penicillin-resistant)| 0.032 － 4|| Streptococcus pneumonia (penicillin-susceptible)| ≤0.004 － 0.25|| Streptococcus pyogenes| ≤0.004 － 2|| |
